1. Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee Sh U. glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev 2017; 18:3-9.
2. Ohka F, Natsume A, Wakabayashi T. Current trends in targeted therapies for glioblastoma multiforme. Neurol Res Int 2012; 2012:878425.
3. Munoz M, Covenas R. Involvement of substance P and the NK-1 receptor in cancer progression. Peptides 2013; 48:1-9.
4. Ebrahimi S, Javid H, Alaei A, Hashemy SI. New insight into the role of substance P/neurokinin-1 receptor system in breast cancer progression and its crosstalk with microRNAs. Clin Genet 2020; 93:322-330.
5. Harrison S, Geppetti P. Substance p. Int J Biochem Cell Biol 2001; 33:555-576.
6. Garcia-Recio S, Gascon P. Biological and pharmacological aspects of the NK1-Receptor. Biomed Res Int 2015; 2015:495704.
7. Suvas S. Role of substance P neuropeptide in inflammation, wound healing, and tissue homeostasis. J Immunol 2017; 199:1543-1552.
8. Javid H, Mohammadi F, Zahiri E, Hashemy SI. The emerging role of substance P/neurokinin-1 receptor signaling pathways in growth and development of tumor cells. J Physiol Biochem 2019; 75:415-421.
9. Javid H, Asadi J, Zahedi Avval F, Afshari AR, Hashemy SI. The role of substance P/neurokinin 1 receptor in the pathogenesis of esophageal squamous cell carcinoma through constitutively active PI3K/Akt/NF-kappaB signal transduction pathways. Mol Biol Rep 2020; 47:2253-2263.
10. Mohammadi F, Javid H, Afshari AR, Mashkani B, Hashemy SI. Substance P accelerates the progression of human esophageal squamous cell carcinoma via MMP-2, MMP-9, VEGF-A, and VEGFR1 over-expression. Mol Biol Rep 2020; 47:4263-4272.
11. Davoodian M, Boroumand N, Mehrabi Bahar M, Jafarian AH, Asadi M, Hashemy SI. Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in breast cancer. Mol Biol Rep 2019; 46:1285-1293.
12. Gharaee N, Pourali L, Jafarian AH, Hashemy SI. Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in endometrial cancer. Mol Biol Rep 2018;45:2257-2262.
13. Lorestani S, Ghahremanloo A, Jangjoo A, Abedi M, Hashemy SI. Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in colorectal cancer. Mol Biol Rep 2020;47:3469-3474.
14. Palma C, Nardelli F, Manzini S. Correlation between binding characteristics and functional antagonism in human glioma cells by tachykinin NK1 receptor antagonists. Eur J Pharmacol 1999; 374:435-443.
15. Palma C, Bigioni M, Irrissuto C, Nardelli F, Maggi C, Manzini S. Anti-tumour activity of tachykinin NK 1 receptor antagonists on human glioma U373 MG xenograft. British Journal of Cancer 2000; 82:480-487.
16. Hennig IM, Laissue JA, Horisberger U, Reubi JC. Substance‐P receptors in human primary neoplasms: Tumoral and vascular localization. Int J Cancer 1995; 61:786-792.
17. Humphreys S, Pellissier J, Jones A. Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK. Cancer Manag Res 2013; 5:215-224.
18. Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): A comprehensive review. Ann Oncol 2015; 26:1081-1090.
19. Robinson P, Taffet G, Engineer N, Khumbatta M, Firozgary B, Reynolds C, et al. Substance P receptor antagonism. Biomed Res Int 2015; 2015:1-12.
20.Muñoz M, Rosso M. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New drugs 2010; 28:187-193.
21. Akazawa T, Kwatra SG, Goldsmith LE, Richardson MD, Cox EA, Sampson JH, et al. A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas. J Neurochem 2009; 109:1079-1086.
22. Springer J, Groneberg DA, Dinh QT, Quarcoo D, Hamelmann E, Braun-Dullaeus RC, et al. Neurokinin-1 receptor activation induces reactive oxygen species and epithelial damage in allergic airway inflammation. Clin Exp Allergy 2007; 37:1788-1797.
23. Gazzieri D, Trevisani M, Springer J, Harrison S, Cottrell GS, Andre E, et al. Substance P released by TRPV1-expressing neurons produces reactive oxygen species that mediate ethanol-induced gastric injury. Free Radic Biol Med 2007; 43:581-589.
24. Liu X, Zhu Y, Zheng W, Qian T, Wang H, Hou X. Antagonism of NK-1R using aprepitant suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes. Artif Cells Nanomed Biotechnol 2019; 47:1628-1634.
25. Li Q, Wu X, Yang Y, Zhang Y, He F, Xu X, et al. Tachykinin NK1 receptor antagonist L-733,060 and substance P deletion exert neuroprotection through inhibiting oxidative stress and cell death after traumatic brain injury in mice. Int J Biochem Cell Biol 2019; 107:154-165.
26. O’Brien J, Wilson I, Orton T, Pognan F. Investigation of the Alamar blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 2000; 267:5421-5426.
27. Sterner-Kock A, Braun RK, van der Vliet A, Schrenzel MD, McDonald RJ, Kabbur MB, et al. Substance P primes the formation of hydrogen peroxide and nitric oxide in human neutrophils. J Leukoc Biol 1999; 65:834-840.
28. Ma J, Altomare A, de la Monte S, Tong M, Rieder F, Fiocchi C, et al. HCl-induced inflammatory mediators in esophageal mucosa increase migration and production of H2O2 by peripheral blood leukocytes. Am J Physiol Gastrointest Liver Physiol 2010; 299:G791-798.
29. Springer J, Pleimes D, Scholz FR, Fischer A. Substance P mediates AP-1 induction in A549 cells via reactive oxygen species. Regul Pept 2005; 124:99-103.
30. Linley JE, Ooi L, Pettinger L, Kirton H, Boyle JP, Peers C, et al. Reactive oxygen species are second messengers of neurokinin signaling in peripheral sensory neurons. Proc Natl Acad Sci U S A 2012; 109:E1578-1586.
31. Mohammadi F, Soltani A, Ghahremanloo A, Javid H, Hashemy SI. The thioredoxin system and cancer therapy: A review. Cancer Chemother Pharmacol 2019; 84:925-935.
32.Hashemy SI. The Human Thioredoxin System: Modifications and Clinical Applications. Iran J Basic Medl Sci 2011; 14:191-204.
33. Sies H. What is oxidative stress? Oxidative stress and vascular disease: Springer; 2000. p. 1-8.
34. Sanchez-Perez Y, Soto-Reyes E, Garcia-Cuellar CM, Cacho-Diaz B, Santamaria A, Rangel-Lopez E. Role of epigenetics and oxidative stress in gliomagenesis. CNS Neurol Disord Drug Targets 2017; 16:1090-1098.
35. Prasad S, Gupta SC, Tyagi AK. Reactive oxygen species (ROS) and cancer: Role of antioxidative nutraceuticals. Cancer Lett 2017; 387:95-105.
36. Afshari AR, Mollazadeh H, Henney NC, Jamialahmad T, Sahebkar A. Effects of statins on brain tumors: a review. Semin Cancer Biol 2020; S1044-579X(20):30173-30175.
37.Jalili-Nik M, Sadeghi MM, Mohtashami E, Mollazadeh H, Afshari AR, Sahebkar A. Zerumbone promotes cytotoxicity in human malignant glioblastoma cells through reactive oxygen species (ROS) generation. Oxidative medicine and cellular longevity 2020; 2020:1-9.
38. Ju KD, Lim JW, Kim KH, Kim H. Potential role of NADPH oxidase-mediated activation of Jak2/Stat3 and mitogen-activated protein kinases and expression of TGF-β1 in the pathophysiology of acute pancreatitis. Inflamm Res 2011; 60:791-800.
39. Vaquero EC, Edderkaoui M, Pandol SJ, Gukovsky I, Gukovskaya AS. Reactive oxygen species produced by NAD (P) H oxidase inhibit apoptosis in pancreatic cancer cells. J Biol Chem 2004; 279:34643-34654.
40. Afshari AR, Roshan MK, Soukhtanloo M, Ghorbani A, Rahmani F, Jalili-Nik M, et al. Cytotoxic effects of auraptene against a human malignant glioblastoma cell line. Avicenna J Phytomed 2019; 9:334.
41. Robinson P, Kasembeli M, Bharadwaj U, Engineer N, Eckols KT, Tweardy DJ. Substance P receptor signaling mediates doxorubicin-induced cardiomyocyte apoptosis and triple-negative breast cancer chemoresistance. BioMed Res Int 2016; 2016.
42. Zhao XN, Bai ZZ, Li CH, Sheng CL, Li HY. The NK-1R Antagonist aprepitant prevents LPS-induced oxidative stress and inflammation in RAW264.7 macrophages. Drug Des Devel Ther 2020; 14:1943-1952.
43. Ge C, Huang H, Huang F, Yang T, Zhang T, Wu H, et al. Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload. Proc Natl Acad Sci U S A 2019; 116:19635-19645.
44. Wu H, Cheng X, Huang F, Shao G, Meng Y, Wang L, et al. Aprepitant Sensitizes Acute Myeloid Leukemia Cells to the Cytotoxic Effects of Cytosine Arabinoside in vitro and in vivo. Drug Des Devel Ther 2020; 14:2413-2422.
45. Aggarwal V, Tuli HS, Varol A, Thakral F, Yerer MB, Sak K, et al. Role of reactive oxygen species in cancer progression: molecular mechanisms and recent advancements. Biomolecules 2019; 9:725-761.
46. Waris G, Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog 2006; 5:14-22.
47. Minutoli L, Puzzolo D, Rinaldi M, Irrera N, Marini H, Arcoraci V, et al. ROS-mediated NLRP3 inflammasome activation in brain, heart, kidney, and testis ischemia/reperfusion injury. Oxid Med Cell Longev 2016; 2016:1-10.
48. Rinaldi M, Caffo M, Minutoli L, Marini H, Abbritti RV, Squadrito F, et al. ROS and brain gliomas: An overview of potential and innovative therapeutic strategies. Int J Mol Sci 2016; 17.
49. Chien CT, Yu HJ, Lin TB, Lai MK, Hsu SM. Substance P via NK1 receptor facilitates hyperactive bladder afferent signaling via action of ROS. Am J Physiol Renal Physiol 2003; 284:F840-851.
50. Chen WC, Shih CC, Lu WA, Li PC, Chen CJ, Hayakawa S, et al. Combination of Wu Lin San and Shan Zha ameliorates substance P-induced hyperactive bladder via the inhibition of neutrophil NADPH oxidase activity. Neurosci Lett 2006; 402:7-11.
51. Serra MC, Bazzoni F, Della Bianca V, Greskowiak M, Rossi F. Activation of human neutrophils by substance P. Effect on oxidative metabolism, exocytosis, cytosolic Ca2+ concentration and inositol phosphate formation. J Immunol 1988; 141:2118-2124.
52. Block ML, Li G, Qin L, Wu X, Pei Z, Wang T, et al. Potent regulation of microglia-derived oxidative stress and dopaminergic neuron survival: substance P vs. dynorphin. FASEB J 2006; 20:251-258.
53. Rao GM, Rao AV, Raja A, Rao S, Rao A. Role of antioxidant enzymes in brain tumours. Clin Chim Acta 2000; 296:203-212.
54. Lillig CH, Holmgren A. Thioredoxin and related molecules--from biology to health and disease. Antioxid Redox Signal 2007; 9:25-47.
55. Arner ES, Holmgren A. The thioredoxin system in cancer. Semin Cancer Biol 2006; 16:420-426.
56. Hattori I, Takagi Y, Nakamura H, Nozaki K, Bai J, Kondo N, et al. Intravenous administration of thioredoxin decreases brain damage following transient focal cerebral ischemia in mice. Antioxid Redox Signal 2004; 6:81-87.
57. Munemasa Y, Kim SH, Ahn JH, Kwong JM, Caprioli J, Piri N. Protective effect of thioredoxins 1 and 2 in retinal ganglion cells after optic nerve transection and oxidative stress. Invest Ophthalmol Vis Sci 2008; 49:3535-3543.
58. Chen Y, Yu M, Jones DP, Greenamyre JT, Cai J. Protection against oxidant-induced apoptosis by mitochondrial thioredoxin in SH-SY5Y neuroblastoma cells. Toxicol Appl Pharmacol 2006; 216:256-262.
59. Haas B, Schutte L, Wos-Maganga M, Weickhardt S, Timmer M, Eckstein N. Thioredoxin Confers Intrinsic Resistance to Cytostatic Drugs in Human Glioma Cells. Int J Mol Sci 2018; 19:2874-2887.